{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:47:04Z","timestamp":1766566024210,"version":"3.48.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Caen-Normandie University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HIV incidence among low-adherence oral PrEP users in PURPOSE 1 and 2 closely matched or slightly exceeded background HIV incidence (bHIV), supporting bHIV as a conservative comparator in PrEP trials. This enables ethical, efficient evaluation of new prevention strategies without placebo arm.<\/jats:p>","DOI":"10.1093\/cid\/ciaf436","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:48:25Z","timestamp":1755085705000},"page":"e375-e377","source":"Crossref","is-referenced-by-count":0,"title":["Background HIV Incidence in PURPOSE 1 and 2 PrEP Trials"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-5590","authenticated-orcid":false,"given":"Jean-Jacques","family":"Parienti","sequence":"first","affiliation":[{"name":"Department of Biostatistics and Clinical Research, Caen University Hospital , Caen ,","place":["France"]},{"name":"INSERM UMR 1311 DYNAMICURE, Universit\u00e9 Caen Normandie , Caen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025122403240097000_ciaf436-B1","first-page":"20190011","article-title":"Advancing novel PrEP products\u2014alternatives to non-inferiority","volume":"11","author":"Glidden","year":"2019","journal-title":"Stat Commun Infect Dis"},{"key":"2025122403240097000_ciaf436-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2830","article-title":"Facilitating next-generation Pre-exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the forum HIV prevention trial design project","volume":"114","author":"Parkin","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2025122403240097000_ciaf436-B3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"2025122403240097000_ciaf436-B4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"2025122403240097000_ciaf436-B5","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"2025122403240097000_ciaf436-B6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2025122403240097000_ciaf436-B7","doi-asserted-by":"crossref","first-page":"e25744","DOI":"10.1002\/jia2.25744","article-title":"Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial","volume":"24","author":"Glidden","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2025122403240097000_ciaf436-B8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11904-007-0024-7","article-title":"Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies","volume":"4","author":"Eaton","year":"2007","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025122403240097000_ciaf436-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf436\/64043976\/ciaf436.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e375\/64043976\/ciaf436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/e375\/64043976\/ciaf436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:24:11Z","timestamp":1766564651000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/5\/e375\/8234283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf436","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,8,14]]}}}